Raed Benkhadra, MD
Medical Oncology · Corvallis, ORNPI 1255837746
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,105 of the $1,296 with a category attached, or 85.3%. 18 manufacturers reported payments, led by Incyte Corporation at 25.3% of the total.
Across 29 payments — averaging $44.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Incyte Corporation$329
- Seagen Inc.$174
- AbbVie$149
- Gilead$125
- Janssen Scientific Affairs, LLC$84
- GSK$67
- plus $368 from 12 others
What the payments were for
- Food & beverage$1,10585%
- Education$19115%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Incyte Corporation | 4 | $329 |
| Seagen Inc. | 2 | $174 |
| AbbVie | 2 | $149 |
| Gilead | 1 | $125 |
| Janssen Scientific Affairs, LLC | 1 | $84 |
| GSK | 3 | $67 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $59 |
| Jazz Pharmaceuticals Inc. | 2 | $59 |
| Lilly USA, LLC | 2 | $41 |
| Regeneron | 1 | $33 |
| Astellas Pharma US Inc | 2 | $29 |
| Novartis | 1 | $28 |
| Tersera Therapeutics LLC | 1 | $27 |
| Deciphera Pharmaceuticals Inc. | 1 | $23 |
| AstraZeneca | 1 | $20 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Daiichi Sankyo Inc. | 1 | $17 |
| Beone Medicines USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,296 in reported general payments places this provider in the 55th percentile of 92 medical oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prochlorperazine Maleate | 15 | $179 |
| Oxycodone Hcl | 11 | $70 |
| Ondansetron Hcl | 13 | $68 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Corvallis
- Herschel WallenCorvallis$11K
- Tina PassalarisCorvallis$769
- Jeff SharmanEugene$264K
- David PagePortland$238K
- Rachel SanbornPortland$233K
- Matthew TaylorPortland$231K
- Tomasz BeerPortland$102K
- Alison ConlinPortland$85K
- Shivaani KummarPortland$66K
- Stacy LewisPortland$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.